Earnings call transcript: Kenvue Q2 2025 sees stock rise despite earnings miss

Kenvue Inc. (KVUE) reported Q2 2025 adjusted EPS of $0.29 and revenue of $3.84 billion, significantly missing analyst expectations by 17.14% and 8.13% respectively, with organic sales declining 4.2%. Despite these financial misses, KVUE's stock increased 1.45% pre-market, signaling investor confidence in the company's strategic initiatives, recent leadership changes, and ongoing comprehensive review of alternatives aimed at portfolio optimization and operational efficiency. Interim CEO Kirk Perry outlined a focus on reducing complexity and improving execution to drive future performance, with the company maintaining a full-year 2025 outlook for low single-digit organic sales decline and adjusted diluted EPS of $1.00-$1.05.

Analysis

Kenvue Inc. reported a significant second-quarter 2025 miss, with adjusted EPS of $0.29 falling 17.14% short of the $0.35 forecast and revenue of $3.84 billion missing expectations by 8.13%. The underperformance was driven by a 4.2% decline in organic sales, attributed to a soft allergy and sun care season, cautious consumer sentiment, and retailer inventory destocking. Despite these poor results and a downward revision of full-year guidance to a low single-digit organic sales decline and $1.00-$1.05 in adjusted EPS, the stock rose 1.45% pre-market. This paradoxical market reaction indicates that investors are looking past the current operational challenges and focusing on the potential for a strategic overhaul under new leadership. The narrative is heavily influenced by the appointment of Interim CEO Kirk Perry, who has articulated a clear strategy to combat "self-induced complexity," simplify the portfolio, and improve execution. The ongoing "comprehensive review of strategic alternatives" by the board further fuels speculation of value-unlocking moves such as divestitures or major restructuring, shifting the stock's valuation basis from current earnings to a forward-looking turnaround story.

Key Decisions for Investors

• Treat Kenvue as a special situation or turnaround investment, where the thesis is primarily based on the new management's ability to execute on its operational overhaul and the outcome of the board's strategic review, rather than near-term financials.
• Investors should closely monitor execution-based key performance indicators such as market share trends in core brands like Listerine and Neutrogena, progress on SKU rationalization, and any announcements regarding portfolio changes or divestitures as proof points of the turnaround.
• Despite the market's forward-looking optimism, maintain a cautious stance given the lowered full-year guidance and significant execution risk; position sizing should reflect the high degree of uncertainty until tangible improvements in operational performance are demonstrated.